LQLY — Qly Biotech Income Statement
0.000.00%
Consumer CyclicalsSpeculativeMicro Cap
Annual income statement for Qly Biotech, fiscal year end - August 31st, USD millions except per share, conversion factor applied.
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 August 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0.004 | 0.004 | 0 |
Cost of Revenue | ||||
Gross Profit | — | 0.003 | 0.003 | 0 |
Selling / General / Administrative Expenses | ||||
Total Operating Expenses | 0.001 | 0.009 | 0.034 | 0.014 |
Operating Profit | -0.001 | -0.005 | -0.029 | -0.014 |
Net Income Before Taxes | -0.001 | -0.005 | -0.029 | -0.014 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.001 | -0.005 | -0.029 | -0.014 |
Net Income Before Extraordinary Items | ||||
Extraordinary Items | ||||
Net Income | -0.001 | -0.005 | -0.029 | -0.014 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.001 | -0.005 | -0.029 | -0.014 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0 | -0.002 | -0.008 | -0.004 |
Dividends per Share |